Healing Co Inc.

$ Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000147793222007571 Filed on October 12, 2022

Income Statement

Concept	2022 Q4	2022 Q2	2022

Balance Sheet

Concept	2022 Q4	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$6.492M
Short-Term Investments
Other Short-Term Assets		$0.00
YoY Change
Inventory		$0.00
Prepaid Expenses		$85.54K
Receivables
Other Receivables
Total Short-Term Assets		$6.577M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment		$0.00
YoY Change
Goodwill		$0.00
YoY Change
Intangibles		$10.71K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$10.71K
YoY Change
TOTAL ASSETS
Total Short-Term Assets		$6.577M
Total Long-Term Assets		$10.71K
Total Assets		$6.588M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$175.0K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$470.4K
YoY Change		66.4%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$470.4K
Total Long-Term Liabilities
Total Liabilities		$470.4K
YoY Change		66.4%
SHAREHOLDERS EQUITY
Retained Earnings		-$8.591M
YoY Change		2529.41%
Common Stock		$44.01K
YoY Change		0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.369M	$6.118M
YoY Change
Total Liabilities & Shareholders Equity		$6.588M
YoY Change

Cashflow Statement

Concept	2022 Q4	2022 Q2	2022

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8261868	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113347	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2331	usd
CY2022Q2	us-gaap	Loans Payable LoansPayable	165304	usd
CY2021Q2	us-gaap	Loans Payable LoansPayable	0	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	0	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3143	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	203615	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7740	usd
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	113347	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001441082
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	thcc	Preferred Stock Designated Shares PreferredStockDesignatedShares	5000000	shares
CY2021Q2	thcc	Preferred Stock Par Value Designated PreferredStockParValueDesignated	0.001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4660000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44004920	shares
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	0	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2021	thcc	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount1 EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount1	0	usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	333-152805
CY2022	dei	Entity Registrant Name EntityRegistrantName	THE HEALING COMPANY INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2862618
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	11th Floor
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ten Grand Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Brooklyn
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11249
CY2022	dei	City Area Code CityAreaCode	866
CY2022	dei	Local Phone Number LocalPhoneNumber	241-0670
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	Yes
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	56036244	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47704920	shares
CY2022	dei	Auditor Name AuditorName	RBSM LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022	dei	Auditor Firm AuditorFirmId	587
CY2022Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	6491937	usd
CY2021Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	85538	usd
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2022Q2	us-gaap	Noncurrent Assets NoncurrentAssets	6577475	usd
CY2021Q2	us-gaap	Noncurrent Assets NoncurrentAssets	0	usd
CY2022Q2	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	10714	usd
CY2021Q2	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	0	usd
CY2022Q2	us-gaap	Assets Assets	6588189	usd
CY2021Q2	us-gaap	Assets Assets	0	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	256534	usd
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	19110	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	37723	usd
CY2021Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	60000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	470444	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	282725	usd
CY2022Q2	us-gaap	Liabilities Liabilities	470444	usd
CY2021Q2	us-gaap	Liabilities Liabilities	282725	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	thcc	Preferred Stock Designated Shares PreferredStockDesignatedShares	7800000	shares
CY2022Q2	thcc	Preferred Stock Par Value Designated PreferredStockParValueDesignated	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4660000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	4660	usd
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44004920	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44000000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	44005	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	44000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14653403	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8590925	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-326725	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	6602	usd
CY2021Q2	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	0	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6117745	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-282725	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6588189	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	0	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2021	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7013890	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69253	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	524819	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	44094	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	138366	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Management Fee Expense ManagementFeeExpense	584794	usd
CY2021	us-gaap	Management Fee Expense ManagementFeeExpense	0	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	8261868	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2331	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8264200	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-113347	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	6602	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8257598	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113347	usd
CY2022	thcc	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.19
CY2021	thcc	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.00
CY2022	thcc	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	44001550	shares
CY2021	thcc	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	44000000	shares
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-169378	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-113347	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-282725	usd
CY2022	thcc	Issuance Of Seed Preferred Stock For Cash Amount IssuanceOfSeedPreferredStockForCashAmount	9320000	usd
CY2022	thcc	Issuance Of Common Stock For Cash Amount IssuanceOfCommonStockForCashAmount	9840	usd
CY2022	thcc	Stock Based Compensation Stock Award StockBasedCompensationStockAward	1885381	usd
CY2022	thcc	Stock Based Compensation Stock Option StockBasedCompensationStockOption	3442847	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8264200	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	6602	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6117745	usd
CY2022	us-gaap	Profit Loss ProfitLoss	8264200	usd
CY2021	us-gaap	Profit Loss ProfitLoss	113347	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	138366	usd
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5328228	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	7938	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	18951	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-29075	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	60000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	205364	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5790	usd
CY2022	thcc	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	8073	usd
CY2021	thcc	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2624257	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47557	usd
CY2022	thcc	Cash Paid To Purchase Noeo CashPaidToPurchaseNoeo	-19800	usd
CY2021	thcc	Cash Paid To Purchase Noeo CashPaidToPurchaseNoeo	0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10714	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-30514	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9329840	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	19613	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2572	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	46210	usd
CY2022	thcc	Payment To Advances Payable Related Parties PaymentToAdvancesPayableRelatedParties	-203615	usd
CY2021	thcc	Payment To Advances Payable Related Parties PaymentToAdvancesPayableRelatedParties	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9148410	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46210	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1702	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6491937	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1347	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1347	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6491937	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022	us-gaap	Reclassifications Reclassifications	RECLASSIFICATION - Certain prior period balances have been reclassified to conform to the current period presentation in the Company’s consolidated financial statements and the accompanying notes. These reclassifications had no effect on net income for the prior periods and reflect the reclassification in the current presentation of $60,000 from accounts payable and accrued expenses, as originally reported at June 30, 2021, to accounts payable – related party in our current report.
CY2021Q2	thcc	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	60000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">USE OF ESTIMATES - The preparation of the financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022	thcc	Assets Acquired AssetsAcquired	141925	usd
CY2022Q2	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	10714	usd
CY2022Q2	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	6241937	usd
CY2021Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2022	thcc	Impaired On Hand Inventory ImpairedOnHandInventory	7938	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	138366	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8590000	usd
CY2022	thcc	Description Of Taxable Income DescriptionOfTaxableIncome	The current year’s net operating loss will carryforward indefinitely, limited to 80% of the current year taxable income
CY2022	thcc	Sale Of Seed Preferred Stock Per Share SaleOfSeedPreferredStockPerShare	2
CY2022Q2	thcc	Stockholders Equity Note Subscriptions Received StockholdersEquityNoteSubscriptionsReceived	9320000	usd
CY2022Q2	thcc	Stockholders Equity Note Subscriptions Receivable Remaining StockholdersEquityNoteSubscriptionsReceivableRemaining	680000	usd
CY2021	thcc	Aggregate Principal Amount Of Term Loan Commitments AggregatePrincipalAmountOfTermLoanCommitments	75000000	usd
CY2022	thcc	Aggregate Principal Amount Of Term Loan Commitments AggregatePrincipalAmountOfTermLoanCommitments	150000000	usd
CY2022Q2	thcc	Intangible Assets Acquired From Noeo March102022 IntangibleAssetsAcquiredFromNoeoMarch102022	141925	usd
CY2022Q2	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	3559	usd
CY2022Q2	thcc	Impairment Of Intangible Assets Noeo ImpairmentOfIntangibleAssetsNoeo	138366	usd
CY2021Q2	us-gaap	Notes Payable NotesPayable	203615	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	530137	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	thcc	Preferred Stock Shares Authorized Increase PreferredStockSharesAuthorizedIncrease	7800000	shares
CY2022Q2	thcc	Number Of Stock Award NumberOfStockAward	3100000	shares
CY2022Q2	thcc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1	3166250	shares
CY2022Q1	thcc	Services Agreement Shares ServicesAgreementShares	100000	shares
CY2022Q2	thcc	Common Stock On Sustained Market Capitalization CommonStockOnSustainedMarketCapitalization	200000	shares
CY2022Q1	thcc	Assuming Average Daily Trading Volume AssumingAverageDailyTradingVolume	100000	shares
CY2022	thcc	Sustained Market Capitalization SustainedMarketCapitalization	400000000	usd
CY2022	thcc	Sharebased Compensation Arrangement By Sharebased Payment Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardVestingRightsPercentage	0.02	pure
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2022	thcc	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriodGross	3100000	shares
CY2022	thcc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Granted Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingGrantedWeightedAverageRemainingContractualTerms	P1Y11M12D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	218750	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2912500	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.75
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3166250	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.001
CY2022	thcc	Weighted Average Remaining Term In Years Granted WeightedAverageRemainingTermInYearsGranted	P10Y
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3166250	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.001
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	621875	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.001
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y9M21D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q2	thcc	Expected Volatility ExpectedVolatility	0.6249	pure
CY2022Q2	thcc	Dividend Yield DividendYield	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1735482	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	23803	usd
CY2022	thcc	Charitable Contributions CharitableContributions	10500	usd
CY2021	thcc	Charitable Contributions CharitableContributions	0	usd
CY2022	thcc	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount1 EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount1	722998	usd
CY2022	thcc	Change In Valuation Allowance Of Income Tax ChangeInValuationAllowanceOfIncomeTax	-1001984	usd
CY2021	thcc	Change In Valuation Allowance Of Income Tax ChangeInValuationAllowanceOfIncomeTax	-23803	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1070176	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	68192	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1070176	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	68192	usd

Files In Submission

Name	View Source	Status
0001477932-22-007571-index-headers.html	Edgar Link	pending
0001477932-22-007571-index.html	Edgar Link	pending
0001477932-22-007571.txt	Edgar Link	pending
0001477932-22-007571-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hlco_10k.htm	Edgar Link	pending
hlco_10kimg34.jpg	Edgar Link	pending
hlco_ex1014.htm	Edgar Link	pending
hlco_ex1014img11.jpg	Edgar Link	pending
hlco_ex1014img12.jpg	Edgar Link	pending
hlco_ex1014img13.jpg	Edgar Link	pending
hlco_ex1014img14.jpg	Edgar Link	pending
hlco_ex1015.htm	Edgar Link	pending
hlco_ex1016.htm	Edgar Link	pending
hlco_ex10161img12.jpg	Edgar Link	pending
hlco_ex10161img13.jpg	Edgar Link	pending
hlco_ex10161img15.jpg	Edgar Link	pending
hlco_ex10161img16.jpg	Edgar Link	pending
hlco_ex10161img17.jpg	Edgar Link	pending
hlco_ex10161img2.jpg	Edgar Link	pending
hlco_ex10161img20.jpg	Edgar Link	pending
hlco_ex10161img21.jpg	Edgar Link	pending
hlco_ex10161img22.jpg	Edgar Link	pending
hlco_ex10161img23.jpg	Edgar Link	pending
hlco_ex10161img24.jpg	Edgar Link	pending
hlco_ex10161img25.jpg	Edgar Link	pending
hlco_ex10161img26.jpg	Edgar Link	pending
hlco_ex10161img27.jpg	Edgar Link	pending
hlco_ex10161img3.jpg	Edgar Link	pending
hlco_ex10161img32.jpg	Edgar Link	pending
hlco_ex10161img33.jpg	Edgar Link	pending
hlco_ex10161img34.jpg	Edgar Link	pending
hlco_ex10161img35.jpg	Edgar Link	pending
hlco_ex10161img4.jpg	Edgar Link	pending
hlco_ex10161img5.jpg	Edgar Link	pending
hlco_ex10161img6.jpg	Edgar Link	pending
hlco_ex10161img7.jpg	Edgar Link	pending
hlco_ex10161img8.jpg	Edgar Link	pending
hlco_ex10161img9.jpg	Edgar Link	pending
hlco_ex1016img36.jpg	Edgar Link	pending
hlco_ex1016img38.jpg	Edgar Link	pending
hlco_ex1016img39.jpg	Edgar Link	pending
hlco_ex1016img7.jpg	Edgar Link	pending
hlco_ex1016img8.jpg	Edgar Link	pending
hlco_ex1016img9.jpg	Edgar Link	pending
hlco_ex1017.htm	Edgar Link	pending
hlco_ex1017img6.jpg	Edgar Link	pending
hlco_ex1017img7.jpg	Edgar Link	pending
hlco_ex1018.htm	Edgar Link	pending
hlco_ex1018img4.jpg	Edgar Link	pending
hlco_ex1018img5.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hlco_ex1018img6.jpg	Edgar Link	pending
hlco_ex1019.htm	Edgar Link	pending
hlco_ex1019img4.jpg	Edgar Link	pending
hlco_ex1019img5.jpg	Edgar Link	pending
hlco_ex1019img6.jpg	Edgar Link	pending
hlco_ex1020.htm	Edgar Link	pending
hlco_ex1020img5.jpg	Edgar Link	pending
hlco_ex1020img6.jpg	Edgar Link	pending
hlco_ex1020img7.jpg	Edgar Link	pending
hlco_ex1020img9.jpg	Edgar Link	pending
hlco_ex1021.htm	Edgar Link	pending
hlco_ex1021img3.jpg	Edgar Link	pending
hlco_ex1021img4.jpg	Edgar Link	pending
hlco_ex1022.htm	Edgar Link	pending
hlco_ex1022img3.jpg	Edgar Link	pending
hlco_ex1022img4.jpg	Edgar Link	pending
hlco_ex1023img18.jpg	Edgar Link	pending
hlco_ex1023img19.jpg	Edgar Link	pending
hlco_ex1024.htm	Edgar Link	pending
hlco_ex1025.htm	Edgar Link	pending
hlco_ex1026.htm	Edgar Link	pending
hlco_ex1026img15.jpg	Edgar Link	pending
hlco_ex1026img16.jpg	Edgar Link	pending
hlco_ex1026img17.jpg	Edgar Link	pending
hlco_ex1026img18.jpg	Edgar Link	pending
hlco_ex1027.htm	Edgar Link	pending
hlco_ex1028.htm	Edgar Link	pending
hlco_ex1029.htm	Edgar Link	pending
hlco_ex21.htm	Edgar Link	pending
hlco_ex311.htm	Edgar Link	pending
hlco_ex312.htm	Edgar Link	pending
hlco_ex321.htm	Edgar Link	pending
hlco_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thcc-20220630.xsd	Edgar Link	pending
thcc_10kimg2.jpg	Edgar Link	pending
thcc_10kimg3.jpg	Edgar Link	pending
thcc_10kimg4.jpg	Edgar Link	pending
thcc-20220630_cal.xml	Edgar Link	unprocessable
thcc-20220630_pre.xml	Edgar Link	unprocessable
thcc-20220630_lab.xml	Edgar Link	unprocessable
hlco_10k_htm.xml	Edgar Link	completed
thcc-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Healing Co Inc.

2022 Q4 Form 10-K Financial Statement

#000147793222007571 Filed on October 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission